Related Experiment Video
Updated: May 10, 2025
04:23
The Creation of a Rat Model for Osteosarcopenia via Ovariectomy
Published on: February 21, 2025
180
Sarcopenia in Parkinson's disease: from pathogenesis to interventions
Meilin Gui1, Lingling Lv1, Shenglan Hu1
1Department of Neurology, Second Xiangya Hospital, Central South University, Changsha 410011, China.
Metabolism: Clinical and Experimental
|April 21, 2025
Summary
Parkinson's disease (PD) and sarcopenia frequently coexist, with sarcopenia worsening PD progression and outcomes. This review explores the mechanisms, assessment, and potential treatments for sarcopenia in PD patients.
Area of Science:
- Gerontology
- Neurology
- Muscle Physiology
Background:
- Parkinson's disease (PD) and sarcopenia are common age-related conditions.
- Sarcopenia affects approximately 20% of PD patients, worsening disease progression, quality of life, and mortality.
- The exact mechanisms linking PD and sarcopenia are not fully understood.
Purpose of the Study:
- To review the mechanisms contributing to sarcopenia in Parkinson's disease.
- To examine current screening and assessment methods for sarcopenia in PD.
- To identify future research directions and therapeutic strategies for sarcopenia in PD.
Main Methods:
- Literature review of studies on PD and sarcopenia.
- Analysis of proposed pathophysiological mechanisms.
- Evaluation of diagnostic and assessment tools.
- Exploration of potential therapeutic interventions.
Main Results:
- Sarcopenia is prevalent in PD and associated with adverse outcomes.
- Potential mechanisms include alpha-synuclein accumulation, motor neuron loss, inflammation, and gut-muscle-brain axis dysfunction.
- Effective screening and assessment are crucial for timely intervention.
Conclusions:
- Understanding the multifaceted mechanisms of sarcopenia in PD is key.
- Further research is needed to develop targeted treatments and risk reduction strategies.
- Integrated approaches addressing muscle health are vital for PD patient care.
Related Concept Videos
01:15Parkinson's Disease: Overview
310
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
310
01:24Parkinson's Disease: Treatment
148
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
148
01:37Neural Regulation
39.0K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.0K
01:22Lysosomal Hydrolases
3.7K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.7K
01:27Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
266
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
266
02:18The Proteasome
8.3K
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
8.3K